Search results
Class 2–4 topical glucocorticoids are the treatment of choice for cutaneous lupus erythematosus (CLE). A randomized, controlled study has shown that fluocinonide 0.05 % is more effective than hydrocortisone 1 % [ 1 ].
Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous subtypes. To date, no therapeutic agents have been licensed specifically for patients with this disease entity and topical and systemic drugs are mostly used “off-label”.
20 gru 2016 · Abstract. Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients with this disease entity, and topical and systemic drugs are mostly used ‘off-label’.
Despite CLE’s demonstrated impact on patients’ quality of life, no drugs for treatment of CLE have been approved by the Food and Drug Administration. One proposed driver of this gap is a focus on SLE rather than its cutaneous counterpart in therapeutic development programmes.
For localized CLE lesions, topical corticosteroids and topical calcineurin inhibitors are first-line treatment. For widespread or severe CLE lesions and (or) cases resistant to topical treatment, systemic treatment including antimalarials and (or) short-term corticosteroids can be added.
6 lut 2017 · Abstract. Objective. To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE). Patients and Methods. A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed. Results.
4 kwi 2020 · Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials. Summary. CLE is a group of complex and heterogenous diseases.
